-
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
•
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA), announced at the 5th China International Import Expo (CIIE). The collaboration will focus on exploring heart failure due to special causes, particularly thyroxine protein amyloid cardiomyopathy (ATTR-CM), aiming to revamp diagnosis and treatment protocols in…
-
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
•
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA), announced at the 5th China International Import Expo (CIIE). The collaboration will focus on exploring heart failure due to special causes, particularly thyroxine protein amyloid cardiomyopathy (ATTR-CM), aiming to revamp diagnosis and treatment protocols in…
-
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in a Phase I clinical study in China for its MRX-8, a new drug against gram-negative drug-resistant bacteria. This marks a significant milestone in the development of MRX-8, which aims to address the growing challenge of…
-
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
•
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study for its Omicron-Delta variant recombinant COVID-19 protein vaccine in Uzbekistan. This marks a significant step in the development of the second-generation vaccine, which targets the Omicron and Delta variants. Previous Clinical StudiesPreviously, Zhifei Bio chose…
-
Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs
•
Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Fuho Capital, with participation from Techsnow Capital and Dingfu Investment. The proceeds will be used to construct the company’s…
-
Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants
•
China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused on dental implants and surgical instruments, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Sunho Capital and MF Capital, with participation…
-
Cyramza Prescribed in China for Advanced Gastric Cancer
•
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai and Beijing Cancer Hospital, marking a new treatment option for second-line advanced gastric cancer patients in China. This milestone follows the drug’s market approval in March 2022 for treating second-line advanced metastatic gastric cancer in…
-
Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus’ development process by utilizing Merck’s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization…
